Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureLi-Yen Mae Huang, Wen-Chang Liao, Chien-Chun Chiou, Jenn-Ping Lou, Philip Hu, Fu-Chang Ko
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Novel treatment for drug-induced toxic epidermal necrolysis (Lyell's syndrome)
10.1159/000083947 · 2005
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
10.1056/nejm199512143332404 · 1995
Stevens-Johnson syndromes and toxic epidermal necrolysis: a review of the literature
10.1016/s1081-1206(10)61112-x · 2005
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
10.1111/j.1365-2133.1996.tb06976.x · 1996
Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study
10.1111/j.1445-5994.2005.00790.x · 2005
Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis—antecedent drug exposures in 99 hospitalized patients
1996
Toxic epidermal necrolysis
10.1016/s0140-6736(97)11369-1 · 1998
Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
10.2165/00128071-200001060-00003 · 2000
Acute and chronic respiratory complications of toxic epidermal necrolysis
10.1097/00004630-199605000-00009 · 1996
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
Toxic epidermal necrolysis (Lyell syndrome)
10.1016/0190-9622(90)70333-d · 1990
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
10.1016/s0140-6736(98)02197-7 · 1998
Medical genetics: a marker for Stevens-Johnson syndrome
10.1038/428486a · 2004
The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification
10.1111/1523-1747.ep12388434 · 1994
T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells
10.1001/archderm.1991.01680050095011 · 1991
Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drug decrease the risk of death?
2000
Experience with toxic epidermal necrolysis treated in a burn center
10.1097/00004630-199601000-00008 · 1996
Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis
10.1097/00004630-199909000-00013 · 1999
Toxic epidermal necrolysis: a retrospective study
10.1046/j.1365-4362.1997.00100.x · 1997
Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids
10.1097/00000658-198611000-00001 · 1986
Treatment of toxic epidermal necrolysis with high-dose intravenous immuno-globulins
10.1001/archderm.139.1.26 · 2003
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression
10.1001/archderm.139.1.33 · 2003
The renal risks of high-dose intravenous immunoglobulin treatment
10.1093/ndt/13.9.2182 · 1998
SCORTEN: a severity of illness score for toxic epidermal necrolysis
10.1046/j.1523-1747.2000.00061.x · 2000
No additional external references are available.